WEBULL
WebtradeDownload

How Wider Q3 Losses Will Impact Relay Therapeutics Stock Investors

Simply Wall St · 1d ago
  • Relay Therapeutics reported Q3 2026 results with a net loss of US$81.75 million and third quarter revenue that was lower than the prior year, alongside nine month revenue of US$3.35 million and a net loss of US$238.74 million.
  • Despite higher cumulative losses and weaker nine month revenue, loss per share narrowed year on year. This points to tighter cost per share even as the pipeline and late stage programs continue to require heavy spending.
  • We will look at how Relay Therapeutics' investment narrative compares with this wider net loss and softer revenue base.

Scan how Relay Therapeutics compares with other high-risk, high-upside stories by reviewing our curated list of 19 high quality undiscovered gems after these Q3 losses and its shrinking revenue base.

Relay Therapeutics Investment Narrative Recap

For Relay Therapeutics, the core belief you would need as a shareholder is that the zovegalisib franchise and broader precision oncology pipeline eventually justify today’s heavy investment. The latest quarter showed a net loss of US$81.75 million and softer nine month revenue of US$3.35 million, but a narrower loss per share. That shift hints at tighter cost per share, even as the late stage program burden remains high.

The biggest near term catalyst still sits with execution of the Phase 3 ReDiscover 2 trial in second line HR+/HER2 PIK3CA mutant breast cancer, plus progress in PI3Kα driven vascular anomalies. Current results do not appear to materially change those clinical timelines. The main operational risk remains sustained high cash burn before any potential commercial pay off from zovegalisib or the rest of the portfolio.

The most relevant recent disclosure is the Q3 2026 earnings release on 4 November. Relay Therapeutics reported a net loss of US$81.75 million for the quarter and US$238.74 million over nine months, paired with revenue of US$3.35 million for the period. Loss per share narrowed to US$0.37 in Q3 and US$1.19 for nine months, even with higher absolute losses.

Those numbers underline the trade off you are making. Relay Therapeutics is still in heavy build out mode, funding multiple registrational efforts around zovegalisib plus work on NRAS and genetic disease programs while remaining unprofitable. The earnings update highlights the importance of careful cash management into 2029, since any setback in key trials or regulatory discussions could extend the loss making phase and raise funding risk.

Relay Therapeutics' current analyst framework points to revenues of US$117.0 million and earnings of US$20.2 million by 2029. This outlook is built on forecast yearly revenue growth of 124.4% and an earnings swing of roughly US$306.2 million from current earnings of a US$286.0 million loss today.

Uncover how Relay Therapeutics' fair value indicates a 53% potential upside to its current price, which could narrow quickly if Relay Therapeutics executes on its pipeline plans.

NasdaqGM:RLAY 1-Year Stock Price Chart
NasdaqGM:RLAY 1-Year Stock Price Chart

Exploring Other Perspectives

One bullish twist on Relay Therapeutics focuses less on near term losses and more on the PIK3CA driven vascular anomalies data. The most optimistic analysts were penciling in 2029 revenue of about US$170.5 million and earnings of US$29.4 million before this Q3 update. That view could shift, so compare these forecasts with other opinions.

Explore another Relay Therapeutics fair value estimate, including one that suggests as much as 53% upside from the current price.

The Verdict Is Yours

Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.

Looking For More Ideas Beyond Relay Therapeutics?

If Relay Therapeutics has sharpened your focus on risk, reward, and runway, it can help to line it up against a broader watchlist. Use the Simply Wall St Screener to scan other opportunities that fit different investing angles, from value to resilience and income.

  • For investors who want potential upside without paying too much for it, check out our 35 high quality undervalued stocks and see which businesses currently trade below their assessed worth.
  • If capital preservation ranks high on your checklist, you can filter for sturdier balance sheets and steadier profiles with a 31 resilient stocks with low risk scores that may help round out a concentrated portfolio.
  • For those building an income focused mix, use the 5 dividend fortresses to spot higher yielding payers that still aim to keep distributions covered.